Abstract: SA-PO0666
Evaluation of KM55 Staining in IgAN as a Predictor of Progression to ESKD
Session Information
- Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - Other
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Eigbire-Molen, Odianosen J., Arkana, Little Rock, Arkansas, United States
- Caza, Tiffany, Arkana, Little Rock, Arkansas, United States
- Stephens, Owen W., Arkana, Little Rock, Arkansas, United States
- Larsen, Christopher Patrick, Arkana, Little Rock, Arkansas, United States
Background
IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide and a leading cause of end-stage kidney disease (ESKD). Identifying reliable histological biomarkers of disease progression remains a critical unmet need. KM55 is a novel staining marker with proposed utility in IgAN. However, its prognostic value in IgAN has not been established.
Methods
We performed a retrospective cohort study of 59 patients with biopsy-proven IgAN, including 29 who progressed to ESKD over a follow-up period of at least 10 years, compared to 30 without disease progression. Inclusion criteria was age less than 50 and exclusion criteria was severe fibrosis, T2. KM55 immunostaining was performed on archived diagnostic kidney biopsy specimens by two pathologists blinded to clinical outcomes. KM55 glomerular staining was scored as positive or negative. Groups were compared using appropriate statistical tests.
Results
Baseline demographical and Oxford MEST-C characteristics for both groups were similar, Figure 1, except for Age and T1 which were higher in the ESRD group, consistent with known IgAN progression. KM55 staining did not differ significantly between patients who progressed to ESKD and those who did not, Figure 2.
Conclusion
In this cohort, KM55 staining of kidney biopsy tissue did not differentiate IgAN patients who progress to ESKD from those with stable kidney function. Further studies are needed to evaluate KM55 in larger cohorts and with established risk stratification using Oxford MEST-C score.
Figure 1: Baseline demographical and Oxford MEST-C characteristics between groups.
Figure 2: KM55 staining did not predict ESKD in this cohort.